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Abstract
Background: Loss of cardiac myocytes due to apoptosis is a relevant feature of ischemic heart disease. It has been described
in infarct and peri-infarct regions of the myocardium in coronary syndromes and in ischemia-linked heart remodeling.
Previous studies have provided protection against ischemia-induced cardiomyocyte apoptosis by the anti-inflammatory
cytokine interleukin-1 receptor-antagonist (IL-1Ra). Mitochondria triggering of caspases plays a central role in ischemia-
induced apoptosis. We examined the production of IL-1Ra in the ischemic heart and, based on dual intra/extracellular
function of some other interleukins, we hypothesized that IL-1Ra may also directly inhibit mitochondria-activated caspases
and cardiomyocyte apoptosis.
Methodology/Principal Findings: Synthesis of IL-1Ra was evidenced in the hearts explanted from patients with ischemic
heart disease. In the mouse ischemic heart and in a mouse cardiomyocyte cell line exposed to long-lasting hypoxia, IL-1Ra
bound and inhibited mitochondria-activated caspases, whereas inhibition of caspase activation was not observed in the
heart of mice lacking IL-1Ra (Il-1ra2/2) or in siRNA to IL-1Ra-interfered cells. An impressive 6-fold increase of hypoxia-
induced apoptosis was observed in cells lacking IL-1Ra. IL-1Ra down-regulated cells were not protected against caspase
activation and apoptosis by knocking down of the IL-1 receptor, confirming the intracellular, receptor-independent, anti-
apoptotic function of IL-1Ra. Notably, the inhibitory effect of IL-1Ra was not influenced by enduring ischemic conditions in
which previously described physiologic inhibitors of apoptosis are neutralized.
Conclusions/Significance: These observations point to intracellular IL-1Ra as a critical mechanism of the cell self-protection
against ischemia-induced apoptosis and suggest that this cytokine plays an important role in the remodeling of heart by
promoting survival of cardiomyocytes in the ischemic regions.
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Introduction
Interleukin-1 (IL-1) receptor antagonist inhibits the inflamma-
tory effects of IL-1a and IL-1b by competing for IL-1 type-I
membrane receptor (IL-1R1) [1,2]. Recently, an often lethal
autoinflammatory syndrome in children (DIRA) [3] has been
linked to genetic deficiency of IL-1Ra. Besides a secreted protein,
three intracellular, unsecreted isoforms of IL-1Ra have been
described in humans, and in mouse tissues both a secreted and an
intracellular isoform have been confirmed [4]. Whereas extracel-
lular IL-1Ra inhibits IL-1 activity by binding to IL-1R1,
intracellular IL-1Ra was recently evidenced to inhibit phosphor-
ilation of proteins involved in IL-1R1 signal transduction in
keratinocytes [5]. Increased serum levels of IL-1Ra have been
found to precede the appearance of markers of heart necrosis and
of inflammation in patients with myocardial ischemic disease [6,7],
suggesting that cardiac myocytes in ischemic heart regions may
synthesize cytokines which influence cell survival. Ischemia-
induced apoptosis is a relevant feature in ischemic heart disease
[8–10]. Previous studies have provided cardioprotection by IL-
1Ra against ischemia-induced cardiomyocyte apoptosis, which
was primarily based on the anti-inflammatory, extracellular
function of IL-1Ra, either by inducing overexpression of IL-1Ra
[11] or by administration of recombinant IL-1Ra [12]. Moreover,
in recent studies substantial cardioprotection against the ischemic
damage was evidenced in coronary ligation experiments per-
formed on mice lacking the IL-1R1 [13], not responsive to IL-1.
Other members of IL-1 family, IL-1a [14] and IL-33 [15], are
nuclear proteins that are released into the extracellular space. This
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observation led to define these cytokines as dual-function, intra/
extracellular molecules [16]. Goal of the study was to examine the
production of IL-1Ra by cardiac myocytes in ischemic heart
disease and to investigate whether endogenous IL-1Ra may
influence cell apoptosis by additional mechanisms besides IL-1Ra
recognized anti-IL-1 function at the IL-1R1 level.
Methods
Patients
Human samples were collected after written informed consent
was obtained in accordance with the Declaration of Helsinki and
with approval by the Independent Ethics Committee of the
University of Udine, Udine, Italy. Myocardial samples were taken
from explanted hearts in 5 patients with ischemic cardiomyopathy
and prior AMI undergoing heart transplantation. All patients had
Figure 1. Expression of IL-1Ra in hearts explanted from patients with end stage ischemic heart disease. (a) Immunofluorescence co-
staining for IL-1Ra and PECAM-1. Several cardiomyocytes show positive staining for IL-1Ra (green), whereas PECAM-1 positive (red) endothelial cells of
myocardial microvessels do not co-stain with IL-1Ra. Cell nuclei are evidenced by DAPI (blue) stain. (b) Co-staining of IL-1Ra (brown) and fibroblast
specific vimentin (red), and (c) of IL-1Ra (brown) and leukocyte/macrophage specific CD14 (red). Nuclei are lightly counterstained by Mayer’s
Hematoxylin. (d) In situ hybridization for IL-1Ra mRNA. Several cardiomyocytes stained positive for the in situ hybridization in a large area of peri-
infarct scar viable myocardium. The inset shows how in situ hybridization is localized mainly in perinuclear areas within cardiomyocytes. (e) Co-
staining for IL-1Ra and active caspase3 in a peri-infarct scar area. Besides IL-1Ra positive cardiomyocytes (brown) there are several caspase3-positive
cells (red). Bars: a–c, e 20 um, d 40 um, insets 10 um. (f) qRT-PCR analyses of sIL-1Ra and icIL-1Ra (type-1, and type-3) mRNA in ischemic
cardiomyopathy, corrected for mRNA expression of b-actin. The graph compares heart regions with macroscopic features of normal blood supply and
trophism (remote) to heart areas close to post infarct scars (peri infarct-scar) and regions 1 cm away from the scars (intermediate). The bars show
mean 6 SE of five experiments.
doi:10.1371/journal.pone.0053265.g001
Intracellular IL-1Ra Function
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e53265
end-stage heart failure (NYHA class IV) and severely impaired
systolic function (left ventricular ejection fraction ,20%), and had
been on a waiting list for transplantation for more than 12 months.
Samples were taken from the explanted hearts in the areas
adjacent to old post infarct scars, in intermediate regions, and in
remote regions. The peri-infarct scar area was defined as the zone
bordering the infarct scar in the left ventricle where viable
myocardium was prevalent and reparative fibrosis only marginal.
Intermediate was defined the area 1 cm distant from the scar, and
remote regions were areas with macroscopic features of normal
blood supply and trophism, several cm distant from infarct scars
but within the same heart ventricle. Samples were frozen at –80uC
within 30 minutes after heart explant, and subsequently analyzed.
Hearts were also taken from a control group of four subjects who
died as consequence of head trauma, and were virtually free of
cardiac disease. In these subjects, hearts were taken at autopsy
shortly after death and heart samples set up for detection of
apoptosis.
Coronary Ligation Model
Procedures were approved by the Animal Care and Use
Committee of Virginia Commonwealth University using US
National Institutes of Health (NIH) guidelines (No. 85-23, revised
1996). C57BL/6 male 8-week-old mice (Harlan Sprague Dawley,
Indianapolis, IN) anesthetized with 50–70 mg per kg body weight
pentobarbital were intubated and subjected to ligation of the
proximal left coronary artery, as previously described [12].
Additional animals underwent a sham operation including every
step except coronary ligation. After completion of the infarction
protocol, animals were sacrificed and hearts were excised and
stored at 280uC.
Il-1ra 2/2 Model
Procedures were approved by the institutional Animal Research
Committee of the University of Trieste, using NIH guidelines.
Mutant mice lacking IL-1Ra (Il-1ra2/2) were generated as
described previously [17]. All comparisons were made to
littermate controls of identical genetic background (C57BL/6J).
Post mortem heart changes were evaluated on male 8-week-old
WT (Il-1ra+/+) or Il-1ra2/2 mouse hearts, which were washed
by perfusion with PBS and rapidly excised from animals as
previously described [12]. Briefly, after sacrifice the abdominal
aorta was cannulated with a polyethylene catheter and filled with
PBS and the right atrium was cut to allow drainage. Hearts were
then excised from animals and immersed in 1–2 drops of PBS on
bottom of polyethylene tubes, and were then incubated at 37uC in
hypoxic (95%N2–5%CO2) conditions in a Micro galaxy, RS
(Biotech) incubator for various periods of time. At each time-point,
hearts were harvested at 280uC. Control samples underwent the
same treatment except incubation.
Cell Culture
Experiments were performed on HL-1 cells, a mouse cardiac
muscle cell line that retains phenotypic characteristics of adult
cardiomyocytes, gift of Dr. W.C. Claycomb [18]. Culture
conditions and media were as previously described [19]. Cells
were grown to confluence on 25 cm2 flasks for enzyme assays, or
on 22-mm glass coverslips placed on the bottom of 35-mm Petri
dishes for immunofluorescence studies. Cells were then incubated
at 37uC either in normoxia or in hypoxia (95% N2-5% CO2)
conditions for up to 9 hr. Cells were then washed and immediately
frozen at 280uC (flasks), or 220uC (coverslips).
siRNA Transfection
HL-1 cells were transfected with siRNA targeted against IL-1Ra
and/or IL-1R1 mRNA. siRNA duplexes targeted against IL-1Ra
(sc-39618-A,-B,-C) or IL-1R1 (sc-35652), or control (sc-37007, sc-
44233) mRNA, and transfection reagents and media were
obtained from Santa Cruz Biotechnology Inc., CA. Cells grown
on 6-well tissue culture plates or glass coverslips were treated for
18 hr with 1 ug targeted siRNA, according to the manufacturer’s
transfection protocol. At 18 h post transfection, cell dishes or
coverslips were incubated at 37uC either in normoxia or in
hypoxia (95% N2 5% CO2) conditions, and then harvested as
described above. Transfection efficiency was evaluated by
immunostaining of glass coverslips with anti-IL-1Ra and/or
anti-IL-1R1 monoclonal Abs and by Western blot analysis for
IL-1Ra and IL-1R1 protein in transfected cell lysates, and
compared to untreated and control siRNA-treated cells. In
addition, functional inactivation of the IL-1R1 was assayed by
RTqPCR analysis of IL-6 RNA expression [5] in transfected cells
after incubation of the cells in the presence or absence of IL-1b,
and compared to untreated or mismatch siRNA (control) treated
cells.
Immunohistochemistry and Immunofluorescence
Cryostat sections of myocardial tissue were fixed for 5 min in
acetone and then incubated for 2 hr in PBS 20% FCS. Unless
specified, Abs were purchased from Santa Cruz. For immunoflu-
orescence studies, treatment with goat anti-C20 human IL-1Ra
Ab was followed by donkey FITC-conjugated anti-goat Ab.
Endothelial cells were stained by mouse monoclonal anti-CD31/
PECAM-1 (Ab M89D3, gift of Dr E. Ferrero) followed by rabbit
anti-mouse RPE-conjugated Ab. Cell nuclei were counterstained
by Hoechst 33342 (Sigma). For IL-1Ra and vimentin, or CD14, or
activated caspase3 co-staining, treatment with goat anti-human
IL-1Ra Ab was followed by donkey anti-goat peroxidase-
conjugated Ab. Peroxidase activity was revealed by brown staining
of oxidized DAB (3,39-Diaminobenzidine, Dako). Sections were
then incubated with anti–vimentin or -active caspase-3 (Chemi-
con), or -CD14 Ab (Promega Madison, WI), followed by Alkaline
Phosphatase labelled polymer (Dako). Alkaline Phosphatase
activity was revealed by FAST RED. A rabbit polyclonal anti-
IL-1Ra (sc-25444) was used as primary antibody on mouse heart
tissue, followed by biotinylated anti-rabbit Ab and streptavidin-
peroxidase VIP (purple) staining (Vector Labs, Burlingame, Ca).
Mouse cardiomyocyte apoptosis was measured by in situ detection
of DNA fragmentation (ApopTag, Chemicon). The apoptotic rate
(AR) was expressed as the number of apoptotic cardiomyocytes on
all cardiomyocytes per field. Cultured cardiomyocytes were
stained with goat anti-mouse IL-1Ra and/or IL-1R1 Ab, followed
by secondary FITC-conjugated donkey anti-goat Ab, and by
either Hoechst 33342 or using the TUNEL fluorescent assay
(Roche, Germany). Controls without primary or secondary
antibodies were run in all experiments. Observations were carried
out by a DM 2000 (Leica, Wetzlar Ge) microscope.
In situ RT-PCR
Expression of IL-1ra RNA in human myocardium samples was
evaluated as previously described [20]. IL-1ra specific primers
were: 59-ATGGAAATCTGCAGA GGCCTC-39; reverse 59-
TGGTTGTTCCTCAGATAGAA GGTCTT-39. No primer
control and no RT control were included in the assay. After the
amplification step, slides were counterstained with Vectashield-
DAPI (Vector). To demonstrate that the correct target segment
was specifically amplified in the in situ PCR reaction, myocardial
samples were used in RT in situ PCR overamplification
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experiments (35 cycles). This procedure allowed the over-pro-
duction of the IL-1Ra desired amplidicon (140 bp, revealed by
agarose gel electrophoresis and ethidium bromide staining) which
was detected in the reaction mixture recovered from myocardial
samples.
Semi-quantitative Real Time-PCR
Samples of human or mouse hearts (approximately 50 mg of
tissue) or cultured cardiomyocytes (approximately 106 cells) were
processed using the GenEluteTM Mammalian Total RNA
Miniprep Kit, (Sigma-Aldrich, St. Louis, MO). The iScript reverse
transcriptase mixture (BioRad Laboratories, Hercules CA) was
then used to synthesize the first-strand cDNA, starting from 1 ug
RNA as template. Real-time quantitative PCR thermo cycling was
conducted using a Rotor-Gene 6000 (Corbett Robotics, Australia).
Real-time semi-quantitative amplifications of human IL-1Ra
isoforms were conducted by means of Custom TaqMan Gene
Expression Assays (Applied Biosystems). Primers and probes were
Figure 2. IL-1Ra protects cardiomyocytes from ischemia-induced apoptosis. (a) Hystochemistry of IL-1Ra expression (purple) in the heart
following coronary artery ligation in mice: ventricle cross section, and (b) specific, diffuse IL-1Ra staining of cardiomyocytes in the ischemic heart area.
(c) Time course of secreted (s) and intracellular (ic) IL-1Ra mRNA expression in the hypoxic heart of WT (Il-1ra+/+) mice. The graphs represent the fold
change after normalization with the expression of b-actin. (d) Histology of TUNEL staining (red stain) of Il-1ra+/+ and (e) Il-1ra2/2mouse hearts after
6 hr hypoxia, and of (f) Il-1ra+/+ and (g) Il-1ra2/2 mouse hearts not exposed to hypoxia. (h) Rate of TUNEL staining in d-g conditions. Results are
means 6 SE, n = 3, **p,0.001 for Il-1ra2/2 vs control Il-1ra+/+ mouse hearts after 6 hr hypoxia, *p,0.001 for Il-1ra+/+ mouse hearts after 6 hr
hypoxia vs hearts not exposed to hypoxia. Bars, a 2 mm, b 20 um; d, e, g, h 40 um.
doi:10.1371/journal.pone.0053265.g002
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Figure 3. IL-1R1-independent anti-apoptotic function of IL-1Ra. (a) Immunofluorescence of IL-1Ra (green) and nuclear DAPI (blue) staining of
cultured mouse cardiomyocytes (HL-1 cells) incubated for 6 hr in normoxia (panel i), or hypoxia (95%N2-5%C02 panel ii) conditions, and (b) rate of IL-
1Ra positive cells (%) in fig. a conditions. (c) Double-immunofluorescence for IL-1Ra and IL-1R1 (both green, panel i), or (d) for IL-1Ra (green, panel i),
Intracellular IL-1Ra Function
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designed for splice variants of the four isoforms of human IL-1Ra,
such that Taqman probes spanned the exon-exon junction.
TaqMan endogenous controls were eukaryotic 18S rRNA, and
human beta actin. A melt curve analysis was performed following
every run to ensure a single amplified product for every reaction.
Real-time PCR amplifications of murine sIL-1Ra and icIL-1Ra
isoforms were conducted using iQ SYBR Green Supermix
(BioRad Laboratories) according to the manufacturer’s instruc-
tions. Primers were: M-il1rn-s (sense ctcatccttctgtttcattcagag,
antisense ccagacttggcacaagacagg, 250 bp), M-il1rn-ic (sense
gtttagctcacccatggcttca, antisense ccagacttggcacaagacagg, 251 bp),
M-beta actin (sense ggctgtattcccctccatcg, antisense ccagttggtaa-
caatgccatgt, 154 bp), M-glucuronidase beta (sense ggctggtgacc-
tactggattt, antisense ggcactgggaacctgaagt, 131 bp). Specificity of
primers was confirmed by BLAST analysis. Results are expressed
as arbitrary mRNA units compared to mRNA expression by
normal control mouse heart tissue, or mouse cardiac myocytes
cultured in aerobic conditions.
Coimmunoprecipitation of Caspases with IL-1Ra and
Western Blots
Immunoprecipitation was conducted on mouse heart tissue or
cultured cardiomyocyte cytosols using polyclonal Abs to IL-1Ra,
or caspases, or control IL-1beta (Santa Cruz), coupled to
Sepharose beads plus protein A/G (Santa Cruz). Precipitates
were washed in PBS and 100 ug fractions were then boiled in SDS
buffer and separated on SDS-PAGE. Blots were probed using
monoclonal Abs (Santa Cruz).
In vitro Caspase Activity
Caspase-3, -6, - 7, and -9 activities were assayed at 22uC, using
a Fluor meter plate reader (BMG Labtech Fluostar, Offenburg,
Germany). The fluorimetry assays were conducted in the kinetic
mode with excitation and emission wavelengths of 400 and
505 nm, respectively. Activity was measured by the release of 7-
amino-4-methylcoumarin (AMC) from the synthetic substrate Ac-
LEHD-AMC for caspase -9, and Ac-DEVD-AMC for terminal
caspases (caspase-3, -7 and -6), respectively. Assay mixtures
contained 104 rpm supernatants (50 mg protein) of cell lysates
[21], or 50 Units of rh-caspases (BioRad Laboratories), increasing
amounts (1–100 mM) of the specific substrate, and caspase buffer
[50 mM HEPES, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS,
10% sucrose and 5 mM dithiothreitol (DTT)]. IL-1b-blocking Abs
(R&D System) were used as internal controls. To determine the
effect of rhIL-1Ra (Amgen, Thousand Oaks, CA) or rh-xIAP (R&
D Systems, Minneapolis, MN) on activity of caspases, assays were
performed in the absence or presence of 0.02–2.0 mM IL-1Ra or
xIAP. Samples were compared to each other based on the activity
of control samples. Data were fitted into the reciprocal Michaelis–
Menten equation, and the i0,5 values were then derived from the
experimental plot, according to Cornish-Bowden [22].
Statistics
Quantitative results are expressed as mean6 s. e. m., or median
and interquartile range for non-parametric variables. SPSS 11.0
for Windows was used for statistical analysis. The ANOVA was
used to compare mean between multiple groups with Bonferroni
corrected T test used to compare 2 groups at a time. The Mann-
Whitney and Wilcoxon tests were used to compare non-paired and
paired non-parametric data, respectively. Two-tailed p values
,0.05 were considered statistically significant.
Results
Synthesis of IL-1Ra in the Human Myocardium
IL-1Ra expression was investigated in myocardial specimens
isolated from heart explants for ischemic cardiomyopathy and
multiple previous AMI. In the areas adjacent to old post infarct
scars (peri-infarct scar regions), 35% [25–40] cardiomyocytes
expressed the IL-1Ra antigen in their cytoplasm. Notably, CD31-
or (e) for IL-1R1 (green, panel i), or (f) for IL-1Ra and IL-1R1 (both green, panel i), respectively, together with TUNEL co-staining (red, panel ii) in the
same field (merge, panel iii) of cultured cardiomyocytes treated with siRNA to both IL-1Ra and IL-1R1, or to IL-1Ra alone, or to IL-1R1 alone, or with
control siRNA, respectively, and exposed to 6 hr hypoxia. Bars, 20 um. (g) Rate of TUNEL positive cells (%) in fig. c-f conditions. Results are means 6
SE, and were obtained using three siRNA probes to IL-1Ra. n = 8. *p,0.001 vs controls. (h) Western blot detection of IL-1Ra and IL-1R1 protein
expression in fig. c-f conditions. (i) RTqPCR analysis of IL-6 mRNA expression in HL-1 cardiomyocytes treated with siRNA to both IL-1Ra and IL-1R1, or
control siRNA, and cultured for 5 hr in the presence or absence of IL-1 beta ((40 pg/ml) or TNF alpha (10 ng/ml), corrected for mRNA expression of
beta-actin. The results confirm down regulation of the IL-1 receptor (IL-R1) in siRNA-treated HL-1 cells. The bars show mean6 SE of four experiments;
*p,0.001 vs activity of TNF alpha-treated controls.
doi:10.1371/journal.pone.0053265.g003
Figure 4. Coimmunoprecipitation of IL-1Ra with mitochondria-
activated caspases. (a) Coimmunoprecipitation of IL-1Ra with
caspase-9 and (b) with caspase-3, -6, and -7 in cultured HL-1
cardiomyocytes after 6 hr hypoxia. Detection by western blot with
monoclonal Abs to caspases or to IL-1Ra, or to control proteins IL-1beta,
IL-1 type I receptor (IL-1R1) and IL-1R Ancillary Protein (IL-1R AcP).
Proteins immunoprecipitated (IP) by Abs to caspases or to IL-1Ra, or to
IL-1beta (control) are compared to unbound (free) supernatant
proteins. The data are compiled from different gels in three separate
experiments; [ ] not detected.
doi:10.1371/journal.pone.0053265.g004
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positive endothelial cells of myocardial microvessels appeared
negative for IL-1Ra antigen. Similarly, vimentin-positive fibro-
blasts and CD14-positive tissue macrophages evidenced in our
samples (less than 1% of the cells, even in proximity of post infarct
scars) appeared negative for IL-1Ra immune staining (Fig. 1A–C).
The rate of cardiomyocytes expressing IL-1Ra decreased to 18%
[5–26] in regions 1 cm away from the scars (intermediate regions),
and to 2.0% [1.0–5.0] in regions with macroscopic features of
normal blood supply and trophism within the same ventricle but
several cm away from infarct scars (remote regions: P,0.001 vs.
peri-infarct scar regions). RT in situ PCR confirmed the actual
synthesis of IL-1Ra in cardiomyocytes (Fig. 1D). The extent of IL-
1Ra mRNA and IL-1Ra protein positive cells were virtually
identical. A potential link between IL-1Ra expression and
cardiomyocyte injury caused by ischemic conditions was then
investigated by comparing IL-1Ra staining to apoptosis, as
revealed by active-caspase3 [9] and IL-1Ra co-staining (Fig. 1E).
Caspase positive cell rates of 2.0% [0.5–2.5] were detected in peri-
infarct scar ‘‘myocardium at risk’’ regions [10], vs 0,4% [0.3–0.5]
in intermediate and vs 0.17% [0.15–0.19] in remote regions,
respectively (P,0.001), thus reflecting the relative proportion of
IL-1Ra expression in the same areas. Hearts from subjects
virtually free of cardiac disease (controls) showed rates of caspase3
and TUNEL positive cells ,0.1% [median 0,04%]. Once
established that cardiomyocytes were the prevalent source of IL-
1ra, expression of mRNA for IL-1Ra was investigated in human
hearts by semi-quantitative real-time PCR. Compared with
remote heart regions, the rates of expression of sIL-1Ra and of
icIL-1 type 1, and type 3 isoforms were ,5 fold higher in the
regions adjacent to post-infarct scars, and ,2 fold higher in the
intermediate regions (Fig. 1F). Consistent with previous observa-
tions in human tissues [23], the mRNA of icIL-1Ra type 2 isoform
was not detectable in any of our samples.
IL-1Ra Synthesis Protects Cardiomyocytes from Ischemia-
induced Apoptosis
In order to establish whether ischemia not followed by
reperfusion may induce IL-1Ra expression in cardiac myocytes,
IL-1Ra synthesis was investigated in mice subjected to an acute
myocardial infarction (AMI) protocol by ligation of the proximal
left coronary artery for up to 6 hours, an established time limit for
survival of myocardial tissue in absence of blood supply, preluding
to oncosic-necrosis changes [10]. Histological examination of
untreated hearts did not show expression of this cytokine. Treated
hearts evidenced a low proportion 5% [4–6] of cardiomyocytes
expressing IL-1ra in 3 hours-treated mice, whereas strong IL-1ra
Figure 5. Cleavage of mitochondria-activated caspases in cardiomyocytes lacking IL-1Ra. (a) Western blot of caspase-9, -3, -6, and -7 from
cultured HL-1 cardiomyocytes untreated (controls) or treated with siRNA to IL-1Ra RNA alone or both IL-1Ra and IL-1R1 RNAs, and then incubated for
6 hr in normoxia (O2+) or hypoxia (O22) conditions. (b) Western blot of caspase-9, -3, -6, and -7 from Il-1ra+/+ (WT) or Il-1ra2/2 (KO) mouse hearts,
before (O2+) and after (O22) 6 hr hypoxia. 3 exp.
doi:10.1371/journal.pone.0053265.g005
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expression by 95% [92–97] cardiomyocytes (p,0.01, 3 exp.) was
evidenced, confined to the ischemic area, in 4.5 and in 6 hours-
treated mice (Fig. 2A, 2B), confirming that ischemia was a potential
stimulus for IL-1ra cardiomyocyte synthesis. To determine the
potential role of IL-1Ra synthesis in protection against ischemia-
induced cardiomyocyte death, we used mice lacking IL-1Ra (Il-
1ra2/2) [17]. In a wide series coronary ligation experiments
performed in previous studies [12] we had experienced that, at
histology, the heart area virtually dependent on blood supplied by
the ligated artery frequently showed fields of normally perfused
tissue, possibly due to collateral vessels. Moreover, 4 to 6 hours
after coronary ligation, we evidenced a patchy bordering of the
ischemic area by neutrophil leukocytes. Thereafter, to exclude the
possible interference with complete ischemia by blood supplied by
collateral vessels as well as a virtual contamination by infiltrating
leukocytes in the coronary ligation model, we analyzed changes in
isolated mouse hearts maintained at 37uC in hypoxic conditions
(95%N2-5%CO2) for various time periods. Quantitative RT-PCR
analysis of the hearts from WT (IL-1Ra +/+) mice showed
a significant increase in both secreted and intracellular IL-1Ra
isoform RNA (Fig. 2C) after 4.5 hr of hypoxia, which decreased to
undetectable levels at 6 hr. Notably, at 4.5 hr of hypoxia, the
increase of icIL-1Ra RNA was as high as 150.065.2 fold, and that
of sIL-1Ra RNA was of 58.265.4 fold, with respect to control
values from hearts immediately after isolation. A low 16% [15–17]
proportion of TUNEL-positive cardiomyocytes was detectable at
6 hr after heart isolation (Fig. 2D). In contrast, 98% [96–99]
TUNEL-positive cardiomyocytes were present in heart samples of
mice lacking IL-1Ra at 6 hr (Fig. 2E), indicating that IL-1Ra
synthesis actually protects cardiomyocytes from hypoxia-induced
death. A very low proportion of TUNEL-positive cardiomyocytes
was evidenced in control samples from Il-1ra+/+ (Fig. 2F) or Il-
1ra2/2 (Fig. 2G) mice not exposed to hypoxia, i.e. 1,1% [0.6–
1.4] in Il-1ra+/+ and 2.5% [1.7–3.4] in Il-1ra2/2 mice (Fig. 2H).
The Anti-apoptotic Function of IL-1ra is IL-1R1-
independent
IL-1Ra expression was further investigated in a cell line of
mouse cardiomyocytes (HL-1 cells) [18]. HL-1 cells cultured in
hypoxic conditions confirmed that hypoxia is a potent stimulus for
IL-1Ra synthesis (Fig. 3A, 3B). RNA interference (siRNA) studies
in which synthesis of either IL-1Ra alone, or IL-1Ra together with
the IL-1 plasma membrane signaling receptor (IL-1R1) had been
down-regulated, confirmed the results obtained in Il-1ra2/2
mouse hearts. Cells from these groups subjected to 6hr-hypoxia
conditions, showed 96% [94–97] TUNEL-positive nuclei with the
double knockdown of IL-1Ra and IL-1R1 (Fig. 3C) as well as with
the knockdown of IL-1Ra alone (Fig. 3D) after 6hr hypoxia, vs
14% [13–15] TUNEL-positive nuclei in controls treated with
siRNA to the IL-1R1 alone (Fig. 3E) or control siRNA(Fig. 3F,
3G). Down regulation of the IL-1R1 in siRNA-treated cells was
confirmed in control experiments by Western blot (Fig. 3H).
Moreover, RTqPCR analysis of IL-6 expression after stimulation
of cardiomyocytes with IL-1b, further confirmed the functional
down regulation [3] of the IL-1R1 in siRNA to IL-1Ra and IL-
Figure 6. In vitro activity of terminal caspases in cardiomyo-
cytes lacking IL-1Ra. Activity of mitochondria-activated terminal
caspases in cytosols of cultured HL-1 cardiomyocytes untreated or
treated with siRNA to IL-1Ra RNA, or both IL-1Ra and IL-1R1 RNAs, and
then incubated for 6 hr in normoxia or hypoxia conditions. Ac-DEVD-
AMC assays compare enzyme activity in the absence (controls) or
presence of anti-IL-1Ra Abs. Bars show means 6 SE of 3 exp.; *p,0.01
vs activity of controls.
doi:10.1371/journal.pone.0053265.g006
Figure 7. IL-1Ra is not inhibited by SMAC. Caspase-9 inhibition by
IL-1Ra or Xiap in the presence and absence of the Xiap inhibitor SMAC,
or Ab to IL-1Ra. Bars show means 6 SE of 3 exp.; *p,0.01 vs activity of
controls.
doi:10.1371/journal.pone.0053265.g007
Figure 8. Hypothetical model of IL-1Ra in the inhibition of
apoptosis. Smac released from ischemia-induced mitochondria which
inhibits the neutralizing effect of IAPs on caspases. Ischemia-induced
IL1ra interacts with caspase-9 and blocks cell death.
doi:10.1371/journal.pone.0053265.g008
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1R1 interfered cells, since siRNA-treated cardiomyocytes in-
creased the expression of IL-6 after stimulation with TNFa, but
not after stimulation with IL-1b (Fig. 3I). With respect to cell
apoptosis, these studies excluded a potential competitive agonistic
activity of IL-1Ra at the IL-1R1 level, since IL-1Ra down-
regulated cells were not protected by knocking down of the
receptor.
IL-1Ra Inhibits Mitochondria-activated Caspases
We then sought to elucidate the intracellular mechanism by
which IL-1Ra would inhibit cell apoptosis. Since activation of
caspase-9 by release of cytochrome-C from mitochondria plays
a central role in ischemia-induced apoptosis [24,25], we looked at
the potential interactions of IL-1Ra with caspase-9 and with
caspases -3, -6, and -7, acting downstream caspase-9 activation in
this cell death pathway. The co-immunoprecipitation experiments
using anti-IL-1Ra or anti-caspase Abs coupled to sepharose beads
demonstrated interaction of both intracellular [4] and secreted IL-
1Ra isoforms with caspase-9 (Fig. 4A) and with caspase-3 (Fig. 4B),
whereas co-immunoprecipitation of IL-1Ra with caspases -6 and -
7, appeared more limited (Fig. 4B). No interaction with caspases
was evidenced for IL-1b and no interaction with IL-1Ra was
evidenced for IL-1R1 ancillary protein (IL-1R AcP), respectively,
used as internal controls in these experiments. Resting caspases
exhibit relative molecular weights (Mw) different from their
activated, cleaved fractions. We compared Mw of caspases in
HL-1 cells cultured in normoxic and 6hr-hypoxia conditions, and
with cell preparations pre-treated with siRNA to IL-1Ra or to IL-
1Ra and IL-1R1 (Fig. 5A). The Mw of protein recognized by anti-
caspase-9 Abs from cells cultured in normoxic conditions was
46 kDa, which corresponded to the Mw of resting-caspase, with
a smaller proportion of 36 kDa caspase-9, compatible with
cleavage during the extraction procedure. After 6hr hypoxia,
a small proportion of caspase-9 from untreated cells was detected
again at 36 kDa, suggesting limited activation of caspase-9. In
contrast, in siRNA-treated cells the bulk of caspase-9 appeared at
36 kDa Mw, indicating increased activation of this enzyme in IL-
1Ra deficient cells with or without concomitant downregulation of
IL-1R1. Similar results were obtained by studying caspase-3, -6,
and -7, as well by comparing caspase-9, -3, -6, and -7 Mw (Fig. 5B)
in IL-1Ra +/+ (WT) and mutant Il-1ra2/2 (KO) 6 hr hypoxia-
treated or untreated mouse hearts. As an additional control, the
effect by siRNA inhibition of IL-1Ra, or both IL-1Ra and IL-1R1
synthesis on mitochondria-dependent caspase activation in
cultured cells was confirmed by incubating cytosols from siRNA-
treated, or untreated-control cells, in the presence of the caspase-3,
-6, and -7 common fluorigenic peptide substrate Ac-DEVD-AMC,
and measuring residual enzyme activity by spectrofluorimetry.
Limited caspase activity was measured in cytosols from normoxic
controls unless cytochrome c and dATP were added to cytosols.
The activity in controls incubated for 6 hr in hypoxic conditions
was significantly enhanced by addition of anti-IL-1Ra Abs
(p,0.001), whereas activity of siRNA-treated cells cultured in
hypoxic conditions peaked without addition of Abs to IL-1Ra.
These results confirm IL-1Ra inhibition of mitochondria-de-
pendent caspase activation in control cells, absent in siRNA
interfered cells (Fig. 6). To compare the inhibitory effect by IL-
1Ra on each of mitochondria-activated caspases, activity of rh-
caspases was measured by spectrofluorimetry in the presence or
absence of rhIL-1Ra. In our conditions, we obtained Km values of
85 mM for caspase-9, and of 5.3 mM, 71 mM and 21 mM for
caspase-3, -6 and -7, respectively, which were in accordance with
previously published data [26]. At substrate Km-concentrations,
IL-1Ra inhibited caspase-9 with i 0,5 values of 0.31 mM. Caspase-
3, -6, and -7 were also inhibited by IL-1Ra, but at concentrations
considered biologically unlikely [27], since i 0,5 for rhIL-1Ra
inhibition of caspase-3, -6, and -7, were 2.5 uM, 2.2 uM, and
1.3 uM, respectively (4 exp., p,0.01), thus suggesting that IL-1Ra
inhibition of caspase-9 in intact cells is, most likely, indirectly
responsible for down regulation of downstream caspases. Smac/
diablo is a protein that is highly expressed in the heart [28,29]. It is
released from the mitochondria along with cytochrome c upon
induction of apoptosis. By binding and sequestering naturally
occurring caspase inhibitors (IAPs), Smac disinhibits caspase
activation. In our assays, the IAP family member Xiap (50 nM)
potently inhibited caspase-9, as expected from previously reported
results [30]. To compare the effect of Smac on caspase inhibition
by Xiap and by IL-1Ra, rh-caspase-9 activity was measured in the
presence of either rh-IL-1Ra or rhXiap, and in the presence or
absence of rhSmac (Fig. 7). In these experiments, Caspase-9 was
equally inhibited by 50 nM Xiap (4462% inhibition) or by
100 nM IL-1Ra (4163% inhibition). As expected, however, Xiap
inhibition was abolished in the presence of Smac (1–1.5 mM)
whereas IL-1Ra inhibition was not influenced at all by up to 3 mM
concentrations of Smac, i.e. 30 fold higher than IL-1Ra
concentration. Notably, IL-1Ra inhibition of Caspase-9 activity
was abolished in the presence of anti-IL-1Ra Abs, used as internal
control in our assays.
Discussion
This study shows synthesis of secreted and intracellular IL-1Ra
isoforms (sIL-1Ra, icIL-1Ra) by cardiomyocytes in ischemic
conditions. IL-1Ra synthesis was observed in cardiomyocytes,
and not in the inflammatory cells or cells of coronary vessels, in
patients with severe ischemic myocardial disease, particularly in
areas of the heart with increased apoptosis, as well as in mouse
cardiomyocytes exposed to enduring ischemic conditions. Previous
studies have shown a very early increase of IL-1Ra, which
preceded the appearance of markers of necrosis in the serum of
patients with AMI, particularly if the AMI was anticipated by pre-
infarction angina [6,7], suggesting that a condition preceding
necrosis may have caused IL-1Ra production. In the present
study, we observed IL-1Ra synthesis in the areas of old post infarct
scars in the human myocardium. Moreover, within scar areas, we
noticed a generalized although not uniform increase of IL-1Ra
positive cells, as compared with other areas of the ventricle,
paralleled by increased rates of myocardiocyte apoptosis. Taken
together, these results suggest that ischemia triggers IL-1Ra
synthesis in cardiomyocytes. It is conceivable that the elevated
serum levels of IL-1Ra in coronary patients are actually due to IL-
1Ra released by ischemic cardiomyocytes, and may have potential
clinical interest for the early diagnosis and prognosis of myocardial
disease.
The results also indicate that IL-1Ra potently inhibits hypoxia-
induced apoptosis in mouse cardiomyocytes, primarily by in-
terfering with caspase-9 activity. Further studies are needed to
quantify the actual role played by each IL-1Ra isoform (icIL-1Ra,
sIL-1Ra) in mediating this intracellular function of IL-1Ra.
However, the binding of both isoforms to caspases evidenced in
supernatants of ischemic cells (Fig. 4) may suggest a combined
activity of sIL-1Ra and of icIL-1Ra in this function. The activation
of caspase-9 plays a critical role in ischemia-induced apoptosis
[31,32]. In response to hypoxia, the mitochondria release
cytochrome c into the cytosol which associates with Apaf-1 and
ATP, triggering activation of caspase-9. Committed caspase-9
further activates downstream effector caspases -3, -6, and -7 that
account for cell phenotype changes associated with apoptotic cell
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death [31]. Release of cytochrome c in cultured cardiomyocytes
has been reported in models of hypoxia [33]. Moreover,
cytochrome c release from mitochondria and caspase-3 activation
were observed in heart samples from patients with end stage
cardiomyopathy [24]. In response to biomechanical and mild
ischemic stress, substantial cardioprotection is achieved by
Apoptosis Repressor with Caspase recruitment domain (ARC)
[34], an anti apoptotic factor that prevents cytochrome c release
and subsequent cell death, by interfering with Bax activation.
However, exposure of cardiomyocytes to ischemia, hypoxia, or
oxidative stress leads cytochrome c release as well as rapid down
regulation of ARC protein levels, thereby abolishing the
cardioprotective role of ARC [34]. In the present study, we show
that ischemia stimulates up to 160 fold increase per time unit of
IL-1Ra production, and that IL-1Ra specifically binds, and
inhibits caspase-9 activity, with i 0,5 in the nano molar range,
and activity of caspases 3, -6 and -7 with i 0,5 in the micro molar
range. These results suggest that IL-1 may substitute for ARC in
enduring ischemic conditions. Among the regulators of apoptosis,
considerable interest has been focusing on the inhibitors of
apoptosis protein (IAP) family, which is an evolutionary conserved
family of proteins that prevent cell death across species. X-linked
IAP (Xiap), a currently known human member of the IAP family,
was reported to inhibit caspase-9 at 10-9 M concentrations [35].
Other IAP family members IAP-1 and -2, and NAIP were
reported to inhibit caspase-3 and -7 at 1028–1027 M concentra-
tions, but not to inhibit caspase-9. The same applies to survivin,
a IAP expressed in human embryonal tissues and tumor lines but
not in adult tissues. Survivin inhibits caspases 3 and 7 as potently
as Xiap, with Kis of 10210 M [36]. Our data indicate that IL-1Ra
inhibits caspase-9 with i 0,5 of 10
27 M, representing 2 logs lower
potency than Xiap, but comparable to the inhibitory effect with
respect to caspase-3 and -7 reported for IAP-1 and -2 [36]. Thus
while the i0,5 obtained for IL-1Ra reflects structural differences
between IL-1Ra and the IAP family members that affect how well
they bind to and inhibit specific caspases, presumably it is
necessary for this protein to be present in the cell at higher
concentrations than XIAP to achieve the same level of protection
against caspase-9, -3, -6 and -7. The observed ,150 fold increase
of IL-1Ra RNA production by ischemic cardiomyocytes may
account for its potential role as a physiologically relevant inhibitor
of caspase-9 and, possibly, also of caspase-3, -6 and -7 mediated
apoptosis in ischemic conditions. Smac, a mitochondria protein
released into the cytosol in response to some of the apoptotic
stimuli, including ischemia [28,29], was found to promote caspase
activation by binding and neutralizing the IAPs, including XIAP,
IAP-1, and IAP-2. Notably, in our assays the anti-caspase-9
activity of IL-1Ra was not affected at all by up to 30 fold higher
concentrations of Smac, suggesting that IL-1 may substitute for
IAPS to inhibit mitochondria activated caspases in ischemic
conditions (Fig. 8).
Recently, Larsen et al. (2009) [37] reported that treatment with
recombinant IL-1Ra caused a significant and long lasting
improvement of b-cell function in type II diabetic patients bearing
a IL-1Ra gene polymorphism associated to reduced IL-1Ra b-cell
expression. Moreover, Aksentijevich el al. (2009) [38] and Reddy
et al. (2009) [39] reported an hitherto unknown association of
a severe autoinflammatory syndrome in 10 patients with
homozygous mutations of IL1RN, the gene encoding IL-1Ra,
leading to the definition of a new syndrome, deficiency of the
Interleukin-1 receptor antagonist [DIRA] [3]. Whether the
pathogenetic component of b-cell impairment cured with exoge-
nous IL-1Ra and the pathogenesis of the DIRA syndrome are to
be reconducted to the failure of extracellular IL-1Ra to compete
with IL-1 at the receptor level and, hence, unopposed proin-
flammatory IL-1 signaling, or for concomitant lack of intracellular
IL-1Ra function remains unclear. It seems possible, however, that
the lack or partial alteration of IL-1Ra anti-apoptotic function
may account, at least in part, for cell loss in ischemic diseases in
which impairment of mitochondria is responsible for the induction
of cell apoptosis.
Acknowledgments
We thank L. Vecile for technical help in histology, and M.G. Hollingshead
and W. Ma for help with animal experiments.
Author Contributions
Provided mutant mice: MJN. Conceived and designed the experiments:
EV AD AA. Performed the experiments: FNS BWVT AF EG SS SC NF.
Analyzed the data: EV AD FNS BWVT AF EG AA GS NF MJN. Wrote
the paper: EV AD AA.
References
1. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of
inflammatory diseases. Blood 117: 3720–3732.
2. Arend WP (1991) Interleukin 1 receptor antagonist. A new member of the
interleukin 1 family. J Clin Invest 88: 1445–1451.
3. Dinarello CA (2009) Interleukin-1beta and the autoinflammatory diseases.
N Engl J Med 360: 2467–2470.
4. Gabay C, Porter B, Fantuzzi G, Arend WP (1997) Mouse IL-1 receptor
antagonist isoforms: complementary DNA cloning and protein expression of
intracellular isoform and tissue distribution of secreted and intracellular IL-1
receptor antagonist in vivo. J Immunol 159: 5905–5913.
5. Banda NK, Guthridge C, Sheppard D, Cairns KS, Muggli M, et al. (2005)
Intracellular IL-1 receptor antagonist type 1 inhibits IL-1-induced cytokine
production in keratinocytes through binding to the third component of the
COP9 signalosome. J Immunol 174: 3608–3616.
6. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, et al. (1999)
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of
hospitalization in unstable angina are associated with increased risk of in-hospital
coronary events. Circulation 99: 2079–2084.
7. Patti G, D’Ambrosio A, Mega S, Giorgi G, Zardi EM, et al. (2004) Early
interleukin-1 receptor antagonist elevation in patients with acute myocardial
infarction. J Am Coll Cardiol 43: 35–38.
8. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, et al. (1997) Apoptosis in the
failing human heart. N Engl J Med 336: 1131–1141.
9. Kostin S, Pool L, Elsa¨sser A, Hein S, Drexler HC, et al. (2003) Myocytes die by
multiple mechanisms in failing human hearts. Circ Res 92: 715–724.
10. Abbate A, Bussani R, Biondi-Zoccai GG, Santini D, Petrolini A, et al. (2005)
Infarct-related artery occlusion, tissue markers of ischaemia, and increased
apoptosis in the peri-infarct viable myocardium. Eur Heart J 26: 2039–2045.
11. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, et al. (2001)
Overexpression of interleukin-1 receptor antagonist provides cardioprotection
against ischemia-reperfusion injury associated with reduction in apoptosis.
Circulation 104 (Suppl 1): I308–I313.
12. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, et al. (2008) Anakinra,
a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in
experimental acute myocardial infarction. Circulation 117: 2670–2683.
13. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, et al. (2011)
Alterations in the Interleukin-1/Interleukin-1 Receptor Antagonist Balance
Modulate Cardiac Remodeling following Myocardial Infarction in the Mouse.
PLoS ONE 6: e27923.
14. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, et al. (2004) The
precursor form of IL-1alpha is an intracrine proinflammatory activator of
transcription. Proc Natl Acad Sci U S A 101: 2434–2439.
15. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, et al. (2007) IL-33,
the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear
factor in vivo. Proc Natl Acad Sci U S A 104: 282–287.
16. Palmer G, Gabay C (2011) Interleukin-33 biology with potential insights into
human diseases. Nat Rev Rheumatol 7: 321–329.
17. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW (2000) Arterial
inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp
Med 191: 303–312.
18. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al.
(1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic
Intracellular IL-1Ra Function
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e53265
characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979–
2984.
19. Recchia AG, Filice E, Pellegrino D, Dobrina A, Cerra MC, et al. (2009)
Endothelin-1 induces connective tissue growth factor expression in cardiomyo-
cytes. J Mol Cell Cardiol 46: 352–359.
20. Boniotto M, Radillo O, Braida L, Pirulli D, Citta` A, et al. (2003) Detection of
MBL-2 gene expression in intestinal biopsies of celiac patients by in situ reverse
transcription polymerase chain reaction. Eur J Histochem 47: 177–180.
21. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995)
Identification and inhibition of the ICE/CED-3 protease necessary for
mammalian apoptosis. Nature 376: 37–43.
22. Corte´s A, Cascante M, Ca´rdenas ML, Cornish-Bowden A (2001) Relationships
between inhibition constants, inhibitor concentrations for 50% inhibition and
types of inhibition: new ways of analysing data. Biochem J 357: 263–268.
23. Gabay C, Smith MF Jr, Arend WP (1999) The human intracellular interleukin 1
receptor antagonist promoter appropriately regulates gene expression in
keratinocytes and gastrointestinal epithelial cells in vivo. Cytokine 11: 561–570.
24. Narula J, Pandey P, Arbustini E, Haider N, Narula N (1999) Apoptosis in heart
failure: release of cytochrome c from mitochondria and activation of caspase-3 in
human cardiomyopathy. Proc Natl Acad Sci U S A 96: 8144–8149.
25. de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA (2000)
Caspase activation and mitochondrial cytochrome C release during hypoxia-
mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol 32: 53–63.
26. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni R, et al.
(1999) Purification and catalytic properties of human caspase family members.
Cell Death Differ 6: 362–369.
27. Ekert PG, Silke J, Vaux DL (1999) Caspase inhibitors. Cell Death Differ 6:
1081–1086.
28. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that
promotes cytochrome c-dependent caspase activation by eliminating IAP
inhibition. Cell 102: 33–42.
29. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, et al. (2000)
Identification of DIABLO, a mammalian protein that promotes apoptosis by
binding to and antagonizing IAP proteins. Cell 102: 43–53.
30. Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) X-linked IAP is
a direct inhibitor of cell-death proteases. Nature 388: 300–304.
31. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, et al. (1997)
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex
initiates an apoptotic protease cascade. Cell 91: 479–489.
32. Zou H, Li Y, Liu X, Wang X (1999) An APAF-1.cytochrome c multimeric
complex is a functional apoptosome that activates procaspase-9. J Biol Chem
274: 11549–11556.
33. Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC III, et al. (1999) ARC
inhibits cytochrome c release from mitochondria and protects against hypoxia-
induced apoptosis in heart-derived H9c2 cells. Circ Res 85: e70–e77.
34. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, et al. (2006) Apoptosis
repressor with caspase recruitment domain is required for cardioprotection in
response to biomechanical and ischemic stress. Circulation 113: 1203–1212.
35. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death’s door.
Nat Rev Mol Cell Biol 3: 401–410.
36. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) The c-IAP-1
and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16:
6914–6925.
37. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, et al. (2009)
Sustained effects of interleukin-1 receptor antagonist treatment in type 2
diabetes. Diabetes Care 32: 1663–1668.
38. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, et al. (2009) An
autoinflammatory disease with deficiency of the interleukin-1-receptor antago-
nist. N Engl J Med 360: 2426–2437.
39. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, et al. (2009) An
autoinflammatory disease due to homozygous deletion of the IL1RN locus.
N Engl J Med 360: 2438–2444.
Intracellular IL-1Ra Function
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e53265
